Maxwell et al. demonstrated that the selective inhibition of IL-17A leads to colitis exacerbation in animals, mainly due to altered epithelial permeability and function; in the same model of colitis, treatment with inhibitors of p40 or p19 subunits showed a significant and comparable reduction of the intestinal inflammation [68]. Here, IL17A is linked to colitis.